AXIM Biotechnologies, Inc. has entered into an exclusive distribution agreement with VisionPlus Corp. to market and distribute AXIM's TearScan Lactoferrin Test for detecting aqueous-deficient dry eye and TearScan IgE Test for ocular allergy throughout South Korea. The partnership represents a strategic expansion into a market experiencing significant growth in ocular health conditions.
Under the agreement terms, VisionPlus receives exclusive rights to distribute both diagnostic tests across South Korea, supported by the I-Peak digital reader. The companies will collaborate on Korean MFDS registration, targeting simultaneous submissions for both assays. VisionPlus will lead local compliance, regulatory coordination, and commercialization through its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers.
The initial agreement term spans one year with automatic one-year renewals for an additional four years, contingent upon meeting annual sales milestones. AXIM will maintain manufacturing control and intellectual-property ownership while providing regulatory and technical support for market entry and ongoing product quality compliance.
This market expansion addresses a growing healthcare concern in South Korea, where VisionPlus President Jerry Park noted the company had anticipated an epidemic of Dry Eye Disease years ago due to increased digital device use and worsening environmental conditions. VisionPlus established dedicated Dry Eye Clinics across Korea in preparation for this emerging healthcare need.
AXIM's TearScan diagnostic portfolio provides quantitative, point-of-care tear biomarker analysis within minutes using minimal tear samples. The system's reader delivers precise measurements that help clinicians differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis. This diagnostic precision is crucial for selecting effective therapies and monitoring patient progress in conditions that often present with overlapping symptoms.
Catalina Valencia, President of AXIM Biotechnologies, emphasized the partnership's significance, stating that VisionPlus's clinical insight and national reach make them ideal for introducing the TearScan platform to South Korea. The collaboration will bring quantitative tear diagnostics directly to clinicians, potentially improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy.
The agreement's importance extends beyond commercial expansion, representing a advancement in ocular healthcare delivery in a region facing increasing incidence of dry eye conditions. By providing rapid, quantitative diagnostic capabilities at the point of care, the partnership could significantly reduce diagnostic delays and improve treatment outcomes for Korean patients. For more information about AXIM's technology, visit https://www.aximbiotech.com.
